Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
出版年份 2017 全文链接
标题
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
作者
关键词
-
出版物
PHARMACOECONOMICS
Volume 35, Issue 8, Pages 831-844
出版商
Springer Nature
发表日期
2017-06-15
DOI
10.1007/s40273-017-0527-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
- (2017) Amy P. Abernethy et al. PLoS One
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
- (2016) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer
- (2015) Keith L. Davis et al. LUNG CANCER
- AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
- (2015) P. Vemer et al. PHARMACOECONOMICS
- Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
- (2014) Anthony J Hatswell et al. Health and Quality of Life Outcomes
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the impact of structural uncertainty in partitioned survival models for oncology
- (2014) J. Beca et al. VALUE IN HEALTH
- The inherent bias from using partitioned survival models in economic evaluation
- (2014) D. Coyle et al. VALUE IN HEALTH
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- Health Care Costs for Patients With Cancer at the End of Life
- (2012) Benjamin Chastek et al. Journal of Oncology Practice
- Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
- (2011) Montserrat Vera-Llonch et al. BMC HEALTH SERVICES RESEARCH
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?
- (2009) R Scott Braithwaite et al. MEDICAL CARE
- Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non–small-Cell Lung Cancer in the United States
- (2009) Kathleen Lang et al. VALUE IN HEALTH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Cost of Care for Elderly Cancer Patients in the United States
- (2008) K. Robin Yabroff et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started